No Data
Exagen Is Maintained at Overweight by Cantor Fitzgerald
Exagen Is Maintained at Overweight by Cantor Fitzgerald
Exagen Price Target Raised to $7.00/Share From $5.00 by Cantor Fitzgerald
Exagen Price Target Raised to $7.00/Share From $5.00 by Cantor Fitzgerald
Canto Fitzgerald: Maintaining the Exagen (XGN.US) rating, adjusted from an increase to an increase in holdings rating, and the target price was adjusted from $5.00 to $7.00.
Canto Fitzgerald: Maintaining the Exagen (XGN.US) rating, adjusted from an increase to an increase in holdings rating, and the target price was adjusted from $5.00 to $7.00.
Cantor Fitzgerald Maintains Overweight on Exagen, Raises Price Target to $7
Cantor Fitzgerald analyst Ross Osborn maintains Exagen (NASDAQ:XGN) with a Overweight and raises the price target from $5 to $7.
Exagen Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/14/2024 326.83% Cantor Fitzgerald $5 → $7 Maintains Overweight 09/26/2023 265.85% Cantor Fitzgerald → $
Exagen's Strong Q1 Earnings and Growth Potential Justify Buy Rating